2 results
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Approved WMOCompleted
This study consists of two research questions: 1. Which treatment (INCS on daily bases versus INCS on demand or versus oral antihistamines on demand) is most effective in reducing nasal symptoms and ocular symptoms in children with mild to moderate…